Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.4M
-
Number of holders
-
114
-
Total 13F shares, excl. options
-
54M
-
Shares change
-
-1.99M
-
Total reported value, excl. options
-
$518M
-
Value change
-
+$17M
-
Put/Call ratio
-
3.25
-
Number of buys
-
67
-
Number of sells
-
-53
-
Price
-
$9.60
Significant Holders of Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share (PSTX) as of Q4 2024
148 filings reported holding PSTX - Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q4 2024.
Poseida Therapeutics, Inc. - Common Stock, par value $0.0001 per share (PSTX) has 114 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54M shares
of 98.4M outstanding shares and own 54.87% of the company stock.
Largest 10 shareholders include FMR LLC (10M shares), Pentwater Capital Management LP (8.63M shares), BlackRock, Inc. (5.63M shares), NOMURA HOLDINGS INC (5.12M shares), VANGUARD GROUP INC (3.83M shares), ALPINE ASSOCIATES MANAGEMENT INC. (2.02M shares), Boxer Capital Management, LLC (2M shares), GEODE CAPITAL MANAGEMENT, LLC (1.63M shares), STATE STREET CORP (1.59M shares), and Aisling Capital Management LP (1.04M shares).
This table shows the top 114 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.